SIGHT SCIEN.INC. DL-,0001

Sight Sciences has appointed Kashif Rashid effective immediately as chief legal officer and corporate secretary. Rashid will receive an annual base salary of $450,000, an annual cash bonus equal to 50% of salary, and RSUs worth $1.4 million that vest over four years starting in 2027. Jeremy Hayden is stepping down as chief legal officer but will remain with the company until August 31, 2026; he was promised a severance equal to one year’s base salary. The company reported second-quarter revenue growth of 20% to $23.4 million, improved margins and raised its full-year guidance, although the stock has recently fallen after an earlier strong weekly performance. » More on de.investing.com

Sight Sciences received FDA 510(k) clearance for its surgical system OMNI Ultra for canaloplasty and trabeculotomy in adults with primary open-angle glaucoma. The implant-free system enables circumferential canaloplasty in a single pass, treats three outflow regions via a corneal microincision and uses TruSync-Plus for controlled viscodilation. OMNI Ultra can be used alone or in combination with cataract surgery; commercial launch in the U.S. is planned for Q4 2026. According to the company, the OMNI platform has already been used in over 350,000 procedures worldwide and is supported by pressure‑lowering clinical studies. » More on de.investing.com

Sight Sciences reports Q1 2026 revenue of $19.7m (+13% YoY), beating expectations by 6.2%. Earnings per share were -$0.24, well below the -$0.17 forecast; net loss was $13m. Gross margin remained steady at 86% and cash and cash equivalents stood at $85m. Management expects further revenue growth, points to product launches such as Omni Ultra, and emphasizes a focus on innovation and market expansion, but notes challenges for near‑term profitability and legal risks. » More on de.investing.com